TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Exercise Training in Type 2 Diabetes and Hypertension
Brief Summary: The coexistence of diabetes and hypertension is damaging to cardiac and peripheral vascular structure and function. Although several health organizations endorse exercise training as a treatment for type 2 diabetes, most studies of exercise and diabetes have focused on controlling blood sugar but not on cardiovascular health. The aim of this study is to determine if exercise training reduces blood pressure and improves cardiovascular health in persons who have both type 2 diabetes and hypertension. An equal number of men and women will be enrolled, and another aim of the study is to examine gender differences in response to exercise training.


Options:
A: Arm Label: Exercise training; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise training for 6 months | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise training for 6 months; Assigned to Arm(s): Exercise training
B: Arm Label: Step Count Prescription Arm; Type: EXPERIMENTAL; Interventions: Behavioral: Step count prescription | Arm Label: Usual care arm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Intervention Type: BEHAVIORAL; Name: Step count prescription; Assigned to Arm(s): Step Count Prescription Arm | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Usual care arm
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Group mediated cognitive behavioral (GMCB) sessions | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Health education sessions | Intervention Type: BEHAVIORAL; Name: Group mediated cognitive behavioral (GMCB) sessions; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Health education sessions; Assigned to Arm(s): 2
D: Arm Label: pedometer-plus-email; Type: EXPERIMENTAL; Interventions: Behavioral: pedometer-plus-email | Arm Label: pedometer-only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: pedometer-only | Intervention Type: BEHAVIORAL; Name: pedometer-plus-email; Assigned to Arm(s): pedometer-plus-email | Intervention Type: BEHAVIORAL; Name: pedometer-only; Assigned to Arm(s): pedometer-only

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Exercise Training in Type 2 Diabetes and Hypertension
Brief Summary: The coexistence of diabetes and hypertension is damaging to cardiac and peripheral vascular structure and function. Although several health organizations endorse exercise training as a treatment for type 2 diabetes, most studies of exercise and diabetes have focused on controlling blood sugar but not on cardiovascular health. The aim of this study is to determine if exercise training reduces blood pressure and improves cardiovascular health in persons who have both type 2 diabetes and hypertension. An equal number of men and women will be enrolled, and another aim of the study is to examine gender differences in response to exercise training.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Walking Exercise | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Walking Exercise | Intervention Type: BEHAVIORAL; Name: Walking Exercise; Assigned to Arm(s): 1, 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diet | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Diet; Assigned to Arm(s): 3
C: Arm Label: Exercise training; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise training for 6 months | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise training for 6 months; Assigned to Arm(s): Exercise training
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Group mediated cognitive behavioral (GMCB) sessions | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Health education sessions | Intervention Type: BEHAVIORAL; Name: Group mediated cognitive behavioral (GMCB) sessions; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Health education sessions; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ONO-7436 Phase II Study - A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy and Safety of ONO-7436 for the Prevention of Cancer Chemotherapy-Induced Nausea and Vomiting in Japan
Brief Summary: The purpose of this study is to examine the efficacy and safety of ONO-7436 for the prevention of cancer chemotherapy-induced nausea and vomiting in patients with malignant tumor


Options:
A: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Drug: aprepitant, Drug: cyclophosphamide, Other: placebo | Arm Label: Arm II; Type: EXPERIMENTAL; Interventions: Drug: aprepitant, Drug: cyclophosphamide, Other: placebo | Intervention Type: DRUG; Name: aprepitant; Assigned to Arm(s): Arm I, Arm II | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): Arm I, Arm II | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm I, Arm II
B: Arm Label: Docetaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel | Arm Label: Docetaxel/Casopitant; Type: EXPERIMENTAL; Interventions: Drug: Casopitant/Docetaxel | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Docetaxel | Intervention Type: DRUG; Name: Casopitant/Docetaxel; Assigned to Arm(s): Docetaxel/Casopitant
C: Intervention Type: DRUG; Name: ONO-7436; Assigned to Arm(s): N/A
D: Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Dexamethasone, Drug: Placebo, Drug: Ondansetron | Arm Label: Single Dose IV; Type: EXPERIMENTAL; Interventions: Drug: Casopitant, Drug: Dexamethasone, Drug: Ondansetron | Intervention Type: DRUG; Name: Casopitant; Assigned to Arm(s): Single Dose IV | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Control, Single Dose IV | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Control | Intervention Type: DRUG; Name: Ondansetron; Assigned to Arm(s): Control, Single Dose IV

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in Japan
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of ONO-8025 (KRP-197) in patients with overactive bladder.


Options:
A: Arm Label: YM178 group; Type: EXPERIMENTAL; Interventions: Drug: YM178 | Arm Label: placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: tolterodine ER group; Type: EXPERIMENTAL; Interventions: Drug: tolterodine ER | Intervention Type: DRUG; Name: YM178; Assigned to Arm(s): YM178 group | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo group | Intervention Type: DRUG; Name: tolterodine ER; Assigned to Arm(s): tolterodine ER group
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tolterodine ER | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Fesoterodine | Intervention Type: DRUG; Name: Tolterodine ER; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Fesoterodine; Assigned to Arm(s): 3
C: Intervention Type: DRUG; Name: ONO-8025 (KRP-197); Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: tolterodine SR, overactive bladder; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label, Randomized, Multicenter Study of the Initiation of Four Dosing Regimens of PROCRIT (Epoetin Alfa) for the Treatment of Anemia of Chronic Kidney Disease (CKD). Protocol Addendum: Due to Space Constraints, See Detailed Description for Full Title of Addendum.
Brief Summary: The primary objective of this study is to compare the change in hemoglobin (Hb) from study start to the end of the study between the every 2 week and the every 4 week dosing regimens in patients with anemia of chronic kidney disease (CKD) initiated on PROCRIT (epoetin alfa). Protocol Addendum: The primary objective of the open-label extension portion of this study is to evaluate if epoetin alfa 40,000 Units given under the skin every six weeks, can maintain hemoglobin within the range of 11-12 g/dL in patients with anemia of CKD.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dynepo (Epoetin delta) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dynepo | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dynepo | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dynepo | Intervention Type: DRUG; Name: Dynepo (Epoetin delta); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Dynepo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Dynepo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Dynepo; Assigned to Arm(s): 4
B: Intervention Type: DRUG; Name: epoetin alfa; Assigned to Arm(s): N/A
C: Arm Label: CERA Treatment Once Monthly; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Darbepoetin Alfa Once Biweekly; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin Alfa Once Biweekly | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): CERA Treatment Once Monthly
D: Arm Label: RO0503821 (1x/2 Weeks); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Darbepoetin (1x/1-2 Weeks); Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin (1x/1-2 Weeks) | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): RO0503821 (1x/2 Weeks)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label, Randomized, Multicenter Study of the Initiation of Four Dosing Regimens of PROCRIT (Epoetin Alfa) for the Treatment of Anemia of Chronic Kidney Disease (CKD). Protocol Addendum: Due to Space Constraints, See Detailed Description for Full Title of Addendum.
Brief Summary: The primary objective of this study is to compare the change in hemoglobin (Hb) from study start to the end of the study between the every 2 week and the every 4 week dosing regimens in patients with anemia of chronic kidney disease (CKD) initiated on PROCRIT (epoetin alfa). Protocol Addendum: The primary objective of the open-label extension portion of this study is to evaluate if epoetin alfa 40,000 Units given under the skin every six weeks, can maintain hemoglobin within the range of 11-12 g/dL in patients with anemia of CKD.


Options:
A: Arm Label: TIW: Epoetin alfa 3 injections Weekly/Once Weekly; Type: EXPERIMENTAL; Interventions: Drug: Epoetin alfa 3 times weekly /once weekly | Arm Label: QW: Epoetin alfa once weekly; Type: EXPERIMENTAL; Interventions: Drug: Epoetin alfa once weekly | Arm Label: Q2W: Epoetin alfa once every two weeks; Type: EXPERIMENTAL; Interventions: Drug: Epoetin alfa once every two weeks | Intervention Type: DRUG; Name: Epoetin alfa 3 times weekly /once weekly; Assigned to Arm(s): TIW: Epoetin alfa 3 injections Weekly/Once Weekly | Intervention Type: DRUG; Name: Epoetin alfa once weekly; Assigned to Arm(s): QW: Epoetin alfa once weekly | Intervention Type: DRUG; Name: Epoetin alfa once every two weeks; Assigned to Arm(s): Q2W: Epoetin alfa once every two weeks
B: Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): N/A
C: Arm Label: Early Epoetin Beta Therapy; Type: EXPERIMENTAL; Interventions: Drug: epoetin beta [NeoRecormon] | Arm Label: Late Epoetin Beta Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: epoetin beta [NeoRecormon] | Intervention Type: DRUG; Name: epoetin beta [NeoRecormon]; Assigned to Arm(s): Early Epoetin Beta Therapy | Intervention Type: DRUG; Name: epoetin beta [NeoRecormon]; Assigned to Arm(s): Late Epoetin Beta Therapy
D: Intervention Type: DRUG; Name: epoetin alfa; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3 Study of the Efficacy and Safety of the Microbicide Carraguard® in Preventing HIV Seroconversion in Women
Brief Summary: The purposes of this study are to determine whether Carraguard® Gel can prevent the transmission of HIV when used during vaginal intercourse, and to confirm that the gel is safe for vaginal use.


Options:
A: Intervention Type: DRUG; Name: Carraguard (PC-515); Assigned to Arm(s): N/A
B: Arm Label: Tenofovir 1% vaginal gel; Type: EXPERIMENTAL; Interventions: Drug: Tenofovir gel | Arm Label: Universal placebo gel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Universal placebo gel | Intervention Type: DRUG; Name: Tenofovir gel; Assigned to Arm(s): Tenofovir 1% vaginal gel | Intervention Type: DRUG; Name: Universal placebo gel; Assigned to Arm(s): Universal placebo gel
C: Intervention Type: DRUG; Name: 1.0% C31G SAVVY vaginal gel; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Cellulose Sulfate gel (6%); Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomized, Double-blind, Three-arm, Placebo-controlled, Multi-center Study to Evaluate the Safety and Efficacy of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)
Brief Summary: The purpose of the study is to determine if cladribine tablets are a safe and effective treatment for relapsing-remitting multiple sclerosis (RRMS).


Options:
A: Arm Label: Rituximab; Type: EXPERIMENTAL; Interventions: Drug: Rituximab | Arm Label: Dimethyl Fumarate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dimethyl fumarate, Drug: Sodium Chloride solution | Arm Label: Sodium Chloride solution; Type: SHAM_COMPARATOR; Interventions: Drug: Dimethyl fumarate, Drug: Sodium Chloride solution | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Rituximab | Intervention Type: DRUG; Name: Dimethyl fumarate; Assigned to Arm(s): Dimethyl Fumarate, Sodium Chloride solution | Intervention Type: DRUG; Name: Sodium Chloride solution; Assigned to Arm(s): Dimethyl Fumarate, Sodium Chloride solution
B: Arm Label: Cladribine 5.25 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Cladribine 5.25 mg/kg | Arm Label: Cladribine 3.5 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Cladribine 3.5 mg/kg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Cladribine 5.25 mg/kg; Assigned to Arm(s): Cladribine 5.25 mg/kg | Intervention Type: DRUG; Name: Cladribine 3.5 mg/kg; Assigned to Arm(s): Cladribine 3.5 mg/kg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 150 mg DAC HYP; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process) | Arm Label: 300 mg DAC HYP; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process) | Intervention Type: BIOLOGICAL; Name: BIIB019 (Daclizumab High Yield Process); Assigned to Arm(s): 150 mg DAC HYP, 300 mg DAC HYP | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Ocrelizumab 600 mg; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab | Arm Label: Ocrelizumab 1000 mg; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab | Arm Label: Avonex; Type: ACTIVE_COMPARATOR; Interventions: Drug: Avonex | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Ocrelizumab; Assigned to Arm(s): Ocrelizumab 1000 mg, Ocrelizumab 600 mg | Intervention Type: DRUG; Name: Avonex; Assigned to Arm(s): Avonex

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomized, Double-blind, Three-arm, Placebo-controlled, Multi-center Study to Evaluate the Safety and Efficacy of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)
Brief Summary: The purpose of the study is to determine if cladribine tablets are a safe and effective treatment for relapsing-remitting multiple sclerosis (RRMS).


Options:
A: Arm Label: FTY720D 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: FTY720D 1.25 mg switch to 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Intervention Type: DRUG; Name: FTY720; Assigned to Arm(s): FTY720D 0.5 mg, FTY720D 1.25 mg switch to 0.5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Fingolimod; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod | Arm Label: Multiple Sclerosis Disease Modifying Treatments (MS DMTs); Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard MS DMTs | Intervention Type: DRUG; Name: Fingolimod; Assigned to Arm(s): Fingolimod | Intervention Type: DRUG; Name: Standard MS DMTs; Assigned to Arm(s): Multiple Sclerosis Disease Modifying Treatments (MS DMTs)
C: Arm Label: Double-blind Natalizumab 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Natalizumab (BG00002) | Arm Label: Double-blind Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Open-label Natalizumab; Type: EXPERIMENTAL; Interventions: Drug: Natalizumab (BG00002) | Intervention Type: DRUG; Name: Natalizumab (BG00002); Assigned to Arm(s): Double-blind Natalizumab 300 mg, Open-label Natalizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Double-blind Placebo
D: Arm Label: Cladribine 5.25 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Cladribine 5.25 mg/kg | Arm Label: Cladribine 3.5 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Cladribine 3.5 mg/kg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Cladribine 5.25 mg/kg; Assigned to Arm(s): Cladribine 5.25 mg/kg | Intervention Type: DRUG; Name: Cladribine 3.5 mg/kg; Assigned to Arm(s): Cladribine 3.5 mg/kg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Vigorous Exercise on Motor Function and Functional Fitness in Juvenile Arthritis
Brief Summary: The objectives of this study are to study the effect of formal exercise training on motor function and overall physical fitness in children with arthritis. A 12-week comprehensive exercise program will be used. Formal exercise training will be compared to Qi gong.


Options:
A: Arm Label: Chiropractic + Exercise; Type: EXPERIMENTAL; Interventions: Other: Chiropractic + Exercise | Arm Label: Exercise; Type: ACTIVE_COMPARATOR; Interventions: Other: Exercise | Intervention Type: OTHER; Name: Chiropractic + Exercise; Assigned to Arm(s): Chiropractic + Exercise | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise
B: Intervention Type: BEHAVIORAL; Name: Aerobic and Qi gong Exercise; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: Aerobic exercise; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Qigong exercise; Assigned to Arm(s): N/A
D: Arm Label: Multimodal Rehabilitation Program; Type: EXPERIMENTAL; Interventions: Behavioral: Multimodal Rehabilitation Program | Arm Label: Care as Usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Care as Usual | Intervention Type: BEHAVIORAL; Name: Multimodal Rehabilitation Program; Assigned to Arm(s): Multimodal Rehabilitation Program | Intervention Type: BEHAVIORAL; Name: Care as Usual; Assigned to Arm(s): Care as Usual

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Sucrose Analgesia in Reducing Pain Responses in Infants Born to Diabetic and Non-diabetic Mothers: A Randomized Controlled Trial
Brief Summary: This study will examine the safety and effectiveness of sugar water to relieve pain in newborn infants during painful blood tests and injections. Infants of diabetic mothers who receive repeated blood tests will be compared to infants of healthy mothers who receive routine painful procedures.

We believe that administration of sucrose analgesia for every painful cutaneous procedure performed after delivery will result in less pain during the newborn infant screening test.


Options:
A: Intervention Type: DRUG; Name: Sucrose; Assigned to Arm(s): N/A
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Other: N2O | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Other: oxygen | Intervention Type: OTHER; Name: N2O; Assigned to Arm(s): A | Intervention Type: OTHER; Name: oxygen; Assigned to Arm(s): B
C: Arm Label: Breast Milk; Type: ACTIVE_COMPARATOR; Interventions: Other: Breast Human Milk | Arm Label: 24 %Sucrose; Type: OTHER; Interventions: Other: 24 % Sucrose | Intervention Type: OTHER; Name: Breast Human Milk; Assigned to Arm(s): Breast Milk | Intervention Type: OTHER; Name: 24 % Sucrose; Assigned to Arm(s): 24 %Sucrose
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: sucrose 24% oral solution | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: sterile water | Intervention Type: DRUG; Name: sucrose 24% oral solution; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: sterile water; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Sucrose Analgesia in Reducing Pain Responses in Infants Born to Diabetic and Non-diabetic Mothers: A Randomized Controlled Trial
Brief Summary: This study will examine the safety and effectiveness of sugar water to relieve pain in newborn infants during painful blood tests and injections. Infants of diabetic mothers who receive repeated blood tests will be compared to infants of healthy mothers who receive routine painful procedures.

We believe that administration of sucrose analgesia for every painful cutaneous procedure performed after delivery will result in less pain during the newborn infant screening test.


Options:
A: Arm Label: Noanalgesia; Type: SHAM_COMPARATOR; Interventions: Procedure: Water 2mL PO 2 minutes prior to intra-muscular injection | Arm Label: Skin-to-skin; Type: EXPERIMENTAL; Interventions: Procedure: skin-to-skin contact | Arm Label: Glucose; Type: EXPERIMENTAL; Interventions: Procedure: Glucose 25% 2 mL PO 2 minutes prior to injection | Arm Label: Skin&Glucose; Type: EXPERIMENTAL; Interventions: Procedure: neonates will receive skin-to-skin contact beginning 2 minutes after the intra-muscular injection and stopping 2 minutes afterwards. | Intervention Type: PROCEDURE; Name: Water 2mL PO 2 minutes prior to intra-muscular injection; Assigned to Arm(s): Noanalgesia | Intervention Type: PROCEDURE; Name: skin-to-skin contact; Assigned to Arm(s): Skin-to-skin | Intervention Type: PROCEDURE; Name: Glucose 25% 2 mL PO 2 minutes prior to injection; Assigned to Arm(s): Glucose | Intervention Type: PROCEDURE; Name: neonates will receive skin-to-skin contact beginning 2 minutes after the intra-muscular injection and stopping 2 minutes afterwards.; Assigned to Arm(s): Skin&Glucose
B: Intervention Type: DRUG; Name: Sucrose; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: Sucrose; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Sucrose solution 30%1 ml; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Breastfeeding; Assigned to Arm(s): N/A

Answer: B